Use of ViviGen® Cellular Bone Matrix results in significantly lower hospital costs compared to rhBMP-2
Use of ViviGen® Cellular Bone Matrix results in significantly lower hospital costs compared to rhBMP-2
Virginia Beach, Va. (Nov. 23, 2020) — ViviGen® Cellular Bone Matrix is associated with significantly lower hospital costs compared to recombinant human bone morphogenetic protein-2 (rhBMP-2), according to an analysis of more than 16,000 U.S. lumbar fusions procedures.